In patients with HR-positive, HER2-negative early breast cancer, the efficacy and safety of ribociclib plus adjuvant endocrine therapy versus endocrine therapy alone are unknown.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: [ Ссылка ]
#oncology #breastcancer #clinicaltrials #nejm
